Novavax (NVAX) Stock Statistics & Valuation Metrics

Novavax has a market cap or net worth of CHF1.21B. The enterprise value is CHF1.13K.

Novavax has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Novavax’s return on equity (ROE) is -3.45 and return on invested capital (ROIC) is 78.00%.

The current PE Ratio of Novavax is ―. Novavax’s PEG ratio is -0.00769.

In the last 12 months, Novavax had revenue of 1.12B and earned 440.30M in profits. Earnings per share was 2.72.

In the last 12 months, operating cash flow was -39.50M and capital expenditures -4.09M, giving a free cash flow of -43.59M billion.

Novavax pays an annual dividend of ―, resulting in a dividend yield of ―

Novavax upcoming earnings date is Nov 5, 2026, After Close (Confirmed).

Novavax as a current ratio of 2.13, with Debt / Equity ratio of -155.00%

In the past 12 months, Novavax has paid 1.86M in taxes.

Novavax EV to EBITDA ratio is 2.23, with an EV/FCF ratio of -4.38.

Novavax has CHF719.34M in cash and marketable securities with CHF295.60M in debt, giving a net cash position of CHF423.74M billion.

Gross margin is 77.85%, with operating margin of 50.14%, and net profit margin of 39.19%.

The average price target for Novavax is CHF11.87, which is 11.43% higher than the current price. The consensus rating is Moderate Buy